<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233060</url>
  </required_header>
  <id_info>
    <org_study_id>CS3005-101</org_study_id>
    <nct_id>NCT04233060</nct_id>
  </id_info>
  <brief_title>A Study of CS3005 in Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects with
      Advanced Solid Tumors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From the day of first dose to 30 days (±7 days) after last dose of CS3005, up to 2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>CS3005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS3005</intervention_name>
    <description>CS3005 will be orally administrated twice daily (BID) until PD, unacceptable toxicity, withdrawal of informed consent, or until maximum treatment duration per protocol (2 years)</description>
    <arm_group_label>CS3005</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General

          1. Be willing and able to provide written informed consent form for the trial.

          2. Male or female between 18 to 75 years of age.

          3. Ability to comply with requirements of the protocol, as assessed by the investigator.

          4. Subjects who were histologically confirmed advanced solid tumor shall have progressed
             disease and/or experienced intolerance from prior standard therapies, or for whom no
             standard of care (SoC) therapies exist.

          5. Subject must have at least one measurable lesion by CT or MRI; radiographic tumor
             assessment should be performed within 28 days prior to the first dose of study
             treatment.

          6. ECOG performance status score of 0 or 1

          7. Prior immunotherapy is allowed

          8. Subjects who have previously received anti-tumor therapy will only be enrolled if the
             toxicities from the previous treatment have returned to the baseline level or NCI
             CTCAE v 5.0 grade ≤1.

          9. Subject must have adequate organ function as indicated by the following laboratory
             values, G-CSF or other relevant medical support within 14 days before the
             administration of the investigational product

         10. Subjects with active hepatitis B or active hepatitis C must receive antiviral
             treatment and pass the HBV DNA titer test and HCV RNA test before being enrolled. The
             subject should be willing to continue effective anti-viral treatment during the study.

         11. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
             result. Either Female or male subjects must agree to use adequate contraceptive
             measures.

        Exclusion Criteria:

          1. Has disease that is suitable for local treatment administered with curative intent

          2. Has a history of a second malignancy active within the previous 3 years except for
             locally curable cancers that have been apparently cured.

          3. Patients with any condition that impairs their ability to take oral medication.

          4. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

          5. Subjects with active, known, or suspected autoimmune disease in the past 3 years prior
             to the start of treatment.

          6. History of active tuberculosis, both pulmonary and extrapulmonary.

          7. Clinically Significant history of cardiac disease within 6 months prior to 1st dosing,
             myocardial infarction within the previous year, or current cardiac ventricular
             arrhythmias requiring medication.

          8. Subjects with ascites, pleural effusion, pericardial effusion which cannot be reversed
             by appropriate interventions.

          9. Subjects with any active infections requiring systemic therapy within 2 weeks prior to
             the initiation of the study treatment.

         10. Known history of positive test for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency syndrome.

         11. History of organ transplant that requires the use of immunosuppressive treatment.

         12. For post immunotherapy patients, with prior ≥ Grade 3, serious, or life-threatening
             immune-mediated reactions following prior anti-PD-(L)1 or other immune-oncology
             therapies.

         13. Subjects who have received systemic anti-tumor treatments 21 days prior to the
             initiation of the study treatment.

         14. Subjects who have received treatment with approved anti-tumor Chinese herbal medicine
             or Chinese prepared.

         15. Subjects with a condition requiring systemic treatment with either corticosteroids or
             other immunosuppressive medications.

         16. Has received treatment with non-selective adenosine antagonist or A2a receptor
             antagonist.

         17. Concurrent administration of strong inhibitors or inducers of CYP3A4 and CYP1A2 is not
             permitted

        For more information regarding trial participation, please contact at
        cstonera@cstonepharma.com
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Li, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CStone Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendie Yuan</last_name>
    <phone>8617621040459</phone>
    <phone_ext>8617621040459</phone_ext>
    <email>cstonera@cstonepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scientia Clinical Research Ltd</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Lemech</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

